Detail akcie Disc Medicine Rg online

Business Summary: Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Disc Medicine Inc revenues was not reported. Net loss increased 90% to $151.7M. Higher net loss reflects Research and development - Balancing v increase of 69% to $113.2M (expense), General and administrative - Balancing increase from $15.7M to $31.6M (expense), Stock-based Compensation in R& increase from $4.9M to $11.2M (expense).